Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

FibroGen Inc

FGEN
Current price
1.12 USD -0.06 USD (-5.08%)
Last closed 1.16 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 112 407 200 USD
Yield for 12 month -93.39 %
1Y
3Y
5Y
10Y
15Y
FGEN
21.11.2021 - 28.11.2021

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.75 USD

P/E ratio

Dividend Yield

Current Year

+147 752 000 USD

Last Year

+140 734 000 USD

Current Quarter

+55 902 000 USD

Last Quarter

+27 138 000 USD

Current Year

+128 904 000 USD

Last Year

+120 454 000 USD

Current Quarter

+30 149 000 USD

Last Quarter

+21 731 000 USD

Key Figures FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -241 032 000 USD
Operating Margin TTM -55.57 %
PE Ratio
Return On Assets TTM -34.39 %
PEG Ratio
Return On Equity TTM -1015.79 %
Wall Street Target Price 1.75 USD
Revenue TTM 167 492 992 USD
Book Value -2.29 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 54.6 %
Dividend Yield
Gross Profit TTM -159 212 000 USD
Earnings per share -2.46 USD
Diluted Eps TTM -2.46 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 53.6 %
Profit Margin -143.56 %

Dividend Analytics FGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 61.3497
Enterprise Value Revenue 0.307
Price Sales TTM 0.869
Enterprise Value EBITDA -0.1735
Price Book MRQ 53.8258

Financials FGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FGEN

For 52 weeks

0.33 USD 17.89 USD
50 Day MA 1.25 USD
Shares Short Prior Month 7 383 409
200 Day MA 1.16 USD
Short Ratio 2.59
Shares Short 7 460 849
Short Percent 8.75 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

441.58 USD Microsoft Corporation +0.8 (+0.18%)
Detailed analytics

ETF funds


S

SX7EEX

13.85 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.35 (-2.26%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics